These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11063600)

  • 1. Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
    Giannotti D; Perrotta E; Di Bugno C; Nannicini R; Harmat NJ; Giolitti A; Patacchini R; Renzetti AR; Rotondaro L; Giuliani S; Altamura M; Maggi CA
    J Med Chem; 2000 Nov; 43(22):4041-4. PubMed ID: 11063600
    [No Abstract]   [Full Text] [Related]  

  • 2. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
    Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
    Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
    Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
    Bellucci F; Carini F; Catalani C; Cucchi P; Lecci A; Meini S; Patacchini R; Quartara L; Ricci R; Tramontana M; Giuliani S; Maggi CA
    Br J Pharmacol; 2002 Jan; 135(1):266-74. PubMed ID: 11786503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of several bicyclic peptide and cyclic pseudopeptide tachykinin NK2 receptor antagonists in the human isolated urinary bladder.
    Giuliani S; Patacchini R; Lazzeri M; Benaim G; Turini D; Quartara L; Maggi CA
    J Auton Pharmacol; 1996 Oct; 16(5):251-9. PubMed ID: 9023669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.
    MacKenzie AR; Marchington AP; Middleton DS; Newman SD; Jones BC
    J Med Chem; 2002 Nov; 45(24):5365-77. PubMed ID: 12431064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis.
    Giolitti A; Cucchi P; Renzetti AR; Rotondaro L; Zappitelli S; Maggi CA
    Neuropharmacology; 2000 Jun; 39(8):1422-9. PubMed ID: 10818258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of [3H]MEN 11420, a novel glycosylated peptide antagonist radioligand of the tachykinin NK2 receptor.
    Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Lippi A; Guelfi M; Quartara L; Maggi CA
    Biochem Biophys Res Commun; 1998 Jul; 248(1):78-82. PubMed ID: 9675089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
    Giolitti A; Altamura M; Bellucci F; Giannotti D; Meini S; Patacchini R; Rotondaro L; Zappitelli S; Maggi CA
    J Med Chem; 2002 Aug; 45(16):3418-29. PubMed ID: 12139452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational rigidity versus flexibility in a novel peptidic neurokinin A receptor antagonist.
    Pavone V; Lombardi A; Maggi CA; Quartara L; Pedone C
    J Pept Sci; 1995; 1(4):236-40. PubMed ID: 9223001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists.
    Quartara L; Fabbri G; Ricci R; Patacchini R; Pestellini V; Maggi CA; Pavone V; Giachetti A; Arcamone F
    J Med Chem; 1994 Oct; 37(21):3630-8. PubMed ID: 7932590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
    Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
    Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: new antagonists for the human tachykinin NK-2 receptor.
    Harmat NJ; Giannotti D; Nannicini R; Perrotta E; Criscuoli M; Patacchini R; Renzetti AR; Giuliani S; Altamura M; Maggi CA
    Bioorg Med Chem Lett; 2002 Feb; 12(4):693-6. PubMed ID: 11844703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological activity of carbohydrate-containing peptidomimetics as new ligands for the human tachykinin NK-2 receptor.
    Capozzi G; Giannini S; Menichetti S; Nativi C; Giolitti A; Patacchini R; Perrotta E; Altamura M; Alberto Maggi C
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2263-6. PubMed ID: 12161112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
    Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
    J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
    Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
    Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of SR 142801 at peripheral tachykinin receptors.
    Patacchini R; Barthò L; Holzer P; Maggi CA
    Eur J Pharmacol; 1995 May; 278(1):17-25. PubMed ID: 7545122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.